(1) the sEPO level in IDA patients of group before treatment, group treated for 1 month and group treated for 2 months was higher than that in normal control group (P < 0.05). The level of sEPO of IDA patients in different groups
after treatment was lower than that in IDA patients of groups before treatment, along with improvement of
anemia status, the level of EPO was gradually reduced, and the level of sEPO in patients of group treated for 3 months was not statistical significant in comparison with that in normal control (P > 0.05). The level of
ferritin in IDA patients before and
after treatment was lower than that in normal control group (P < 0.05). The level of
ferritin in IDA patient of groups
after treatment was all higher than that in patients of groups before treatment, but comparision of serum
ferritin level in patients of groups
after treatment did not show statistical significance. (2) The level of logEPO in IDA patient before and
after treatment was negatively related with level of Hb, but the level of
ferritin in IDA patients was positively related with the level of Hb before treatment (r = 0.449, P = 0.005), the level of
ferritin in patients of different group
after treatment and in normal group did not related with level of HB. (3) The level of serum EPO in patients of severe
anemia group was obviously higher than that in patients of moderate and mild
anemia groups, and along with aggravation of
anemia, the EPO level was gradually arised.
CONCLUSION: The serum EPO is involved in the process of erythrocyte hematopoiesis, and can indicate the level of
anemia, its sensitivity for
anemia is higher than that of
ferritin, and has important clinical value for evaluating status of diseases, observing therapeutic efficacy and judging prognosisi of IDA.